Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026

British Journal of Cancer

Volumn 93, Issue 9, 2005, Pages 1011-1018

  Nutley, B P ^a   Smith, N F ^a,d   Hayes, A ^a   Kelland, L R ^a,e   Brunton, L ^a   Golding, B T ^b   Smith, G C M ^c   Martin, N M B ^c   Workman, P ^a   Raynaud, F I ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c KuDOS Pharmaceuticals Ltd   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Antisoma plc   (United Kingdom)

Author keywords

DNA PK; Metabolism; NU7026; Pharmacokinetics

Indexed keywords

2 (2,6 DIMETHYLMORPHOLIN 4 YL)PYRIMIDO[2,1 A]ISOQUINOLIN 4 ONE; 2 (MORPHOLIN 4 YL)BENZO[H]CHROMEN 4 ONE; 2 [2 (2 HYDROXYETHOXY)ETHYLAMINO]BENZO[H]CHROMEN 4 ONE; 2 [BIS(2 HYDROXYETHYL)AMINO]BENZO[H]CHROMEN 4 ONE; 4 (MORPHOLIN 4 YL) 6 METHOXY 1 BENZOPYRAN 2 ONE; DNA DEPENDENT PROTEIN KINASE INHIBITOR; MORPHOLINE DERIVATIVE; NU 7026; NU 7031; NU 7107; NU 7199; NU 7200; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOSENSITIZATION;

ANIMALS; BIOLOGICAL AVAILABILITY; CELL PROLIFERATION; CHROMONES; DNA-ACTIVATED PROTEIN KINASE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; GAMMA RAYS; HUMANS; MICE; MICE, INBRED BALB C; MORPHOLINES; OVARIAN NEOPLASMS; RADIATION TOLERANCE; TUMOR STEM CELL ASSAY;

EID: 27644509749     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602823     Document Type: Article

References (33)

1. Auckley DH, Crowell RE, Heaphy ER, Stidley CA, Lechner JF, Gilliland FD, Belinsky SA (2001) Reduced DNA-dependent protein kinase activity is associated with lung cancer. Carcinogenesis 22: 723-728
2. Baker GB, Urichuk LJ, McKenna KF, Kennedy SH (1999) Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 19: 411-426
3. Chernikova SB, Wells RL, Elkind MM (1999) Wortmannin sensitizes mammalian cells to radiation by inhibiting theDNA-dependent protein kinase-mediated rejoining of double-strand breaks. Radiat Res 151: 159-166
4. Chiosis G, Rosen N, Sepp-Lorenzino L (2001) LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett 11: 909-913
5. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE (2002) Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 62: 4671-4677
6. Eriksson A, Lewensoh R, Larsson R, Nilsson A (2002) DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity. Anticancer Res 22: 787-793
7. Featherstone C, Jackson SP (1999) DNA-dependent protein kinase gets a break: its role in repairing DNA and maintaining genomic integrity. Br J Cancer 9: 759-761
8. Fugmann SD (2002) DNA repair: breaking the seal. Nature 18: 691-694
9. Fukuchi K, Watanabe H, Tomoyasu S, Ichimura S, Tatsumi K, Gomi K (2000) Phosphatidylinositol 3-kinase inhibitors, Wortmannin or LY294002, inhibited accumulation of p21 protein after gamma-irradiation by stabilization of the protein. Biochim Biophys Acta 1496: 207-220
10. Griffin RJ, Fontana G, Golding BT, Guiard S, Hardcastle IR, Leahy JJ, Martin N, Richardson C, Rigoreau L, Stockley M, Smith GC (2005) Selective benzopyranone and pyrimido[2,1-a]isoquiolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitisation of a human tumor cell line in vitro. J Med Chem 48: 569-585
11. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, McKenna WG (2003) Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56: 846-853
12. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB (2000) In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 3: 880-886
13. Huskey SE, Dean BJ, Doss GA, Wang Z, Hop CE, Anari R, Finke PE, Robichaud AJ, Zhang M, Wang B, Strauss JR, Cunningham PK, Feeney WP, Franklin RB, Baillie TA, Chiu SH (2004) The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab Dispos 32: 246-258
14. Jackson SP (1997) DNA-dependent protein kinase. Int J Biochem Cell Biol 29: 935-938
15. Kim CH, Park S, Lee SH (2002) A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation. J Pharmacol Exp Ther 303: 753-759
16. Langner A, Ratzer J, Rickert H, Nerlich C, Franke P (1993) The biotransformation of the anticonvulsant 4-p-chlorophenylpyrrol-3-morpholino-2- carboxylic acid methyl ester (AWD 140-076). Pharmazie 48: 849-853
17. Lee SH, Kim CH (2002) DNA-dependent protein kinase complex: a multifunctional protein in DNA repair and damage checkpoint. Mol Cell 13: 159-166
18. Martin NM (2001) DNA repair, inhibition and cancer therapy. J Photochem Photobiol 63: 162-170
19. Moll U, Lau R, Sypes MA, Gupta MM, Anderson CW (1999) DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. Oncogene 18: 3114-3126
20. Nutley B, Raynaud FI, Hayes A, Goddard P, Jarman M, Workman P (2001) Pharmacokinetics and metabolism of the phosphatidylinositol 3-kinase inhibitor LY294002 in the mouse. Clin Cancer Res 42: 380
21. Okayasu R, Suetomi K, Yu Y, Silver A, Bedford JS, Cox R, Ullrich RL (2000) A deficiency in DNA repair and DNA-PKcs expression in the radiosensitive BALB/c mouse. Cancer Res 60: 4342-4345
22. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD (1997) Radiosensitization of human tumor cells by the phosphatidylinositol 3-kinaseinhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 3: 1149-1156
23. Sak A, Stuschke M, Wurm R, Schroeder G, Sinn B, Wolf G, Budach V (2002) Selective inactivation of DNA-dependent protein kinase with antisense oligodeoxynucleotides: consequences for the rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer cell lines. Cancer Res 62: 6621-6624
24. Semba S, Itoh N, Ito M, Harada M, Yamakawa M (2002) The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res 8: 1957-1963
25. Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E, Halbrook J, Kesicki EA, Kashishian A, Hallahan DE (2005) DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 12(65): 4987-4992
26. Vaganay-Juery S, Muller C, Marangoni E, Abdulkarim B, Deutsch E, Lambin P, Calsou P, Eschwege F, Salles B, Joiner M, Bourhis J (2000) Decreased DNA-PK activity in human cancer cells exhibiting hypersensitivity to low-dose irradiation. Br J Cancer 83: 514-518
27. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW (2003) Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 63: 6008-6015
28. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW (2004) Effects of novel inhibitors of poly(ADP-ribose)polymerase-1 DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 23: 7322-7329
29. Workman P, Balmain A, Hickman JA, McNally NJ, Mitchison NA, Pierrepoint CG, Raymond R, Rowlat C, Stevens TC, Wallace J (1997) United Kingdom Co-ordinating Committee on Cancer Research (UKCCR) guidelines for the welfare of animals in experimental neoplasia. Second edition UKCCR. Br J Cancer 77: 1-10
30. Yarnold J (1997) Molecular aspects of cellular responses to radiotherapy. Radiother Oncol 44: 1-7
31. Yoshida M, Hosoi Y, Miyachi H, Ishii N, Matsumoto Y, Enomoto A, Nakagawa K, Yamada S, Suzuki N, Ono T (2002) Roles of DNA-dependent protein kinase and ATM in cell-cycle-dependent radiation sensitivity in human cells. Int J Radiat Biol 78: 503-512
32. Zhang Q, Ma P, Wang W, Cole RB, Wang G (2004) Characterization of rat liver microsomal metabolites of AM-630, a potent cannabinoid receptor antagonist, by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. J Mass Spectrom 39: 672-681
33. Zhao ZZ, Qin XZ, Wu A, Yuan Y (2004) Novel rearrangements of an N-oxide degradate formed from oxidation of a morpholine acetal substance P antagonist. J Pharm Sci 93: 1957-1961